2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, Budde L, Caimi P, Chang J, Christian B, DeVos S, Dholaria B, Fayad L, Habermann T, Hamid M, Hernandez-Ilizaliturri F, Hu B, Kaminski M, Karimi Y, Kelsey C, King R, Krivacic S, LaCasce A, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts K, Saeed H, Smith S, Svoboda J, Swinnen L, Tuscano J, Vose J, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 1118-1131. PMID: 37935098, DOI: 10.6004/jnccn.2023.0057.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellT-LymphocytesConceptsB-cell lymphomaMantle cell lymphomaCAR T-cell therapyT-cell therapyTyrosine kinase inhibitorsFollicular lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyRefractory B-cell lymphomaTreatment of FLBispecific T-cell engagersBruton tyrosine kinase inhibitorsLarge B-cell lymphomaNCCN Guidelines InsightsRefractory follicular lymphomaNovel immunotherapeutic approachesRelapsed Follicular LymphomaT-cell engagersTreatment landscapeImmunotherapeutic approachesFrontline settingTreatment optionsCell lymphomaLymphomaTherapy
2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 1218-1230. PMID: 34781267, DOI: 10.6004/jnccn.2021.0054.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CD19HumansImmunoconjugatesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinConceptsB-cell lymphomaNCCN guidelinesAnti-CD19 CAR T-cell therapyB-cell non-Hodgkin lymphomaCAR T-cell therapyB-cell receptor pathwayLarge B-cell lymphomaNCCN Guidelines InsightsRelapsed/refractoryT-cell therapyNon-Hodgkin lymphomaNovel treatment optionsMantle cell lymphomaAntibody-drug conjugatesR diseaseTherapy optionsTreatment optionsCell lymphomaFollicular lymphomaSmall molecule inhibitorsLymphomaMolecular pathogenesisReceptor pathwayMolecule inhibitorsTherapy
2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFL